PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Operating Income Margin for the year ending December 31, 2023

PainReform Ltd. Operating Income Margin is NA for the year ending December 31, 2023. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

PainReform Ltd. Operating Income Margin for the year ending December 31, 2022 was -10,312.79%.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years